Trial reportBMC anesthesiology2025
Effect of liposomal bupivacaine for sciatic nerve block on opioid use in patients undergoing maxillofacial reconstruction with free fibular flap: a randomized, controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWe investigated the efficacy and safety of preoperative popliteal sciatic nerve block (PSNB) using liposomal bupivacaine (LB) to reduce perioperative opioid consumption and improve recovery quality in patients undergoing maxillofacial reconstruction with a free fibular flap.
methodsA total of 74 patients were randomly allocated into two groups. The PSNB group received ultrasound guided PSNB using 133 mg of LB after anesthesia induction. In the control group, patients underwent nerve block preparation procedures without puncture or drug injection. The primary endpoint was cumulative opioid consumption during the perioperative period (from anesthesia induction to 48 h post-surgery). The secondary endpoints were the total incidence of moderate to severe pain during the 48 h postoperative period; the incidence of moderate to severe pain during different time periods after surgery; the incidence of PONV within 48 h after surgery; subjective sleep quality within 2 days after surgery; the length of post-surgical hospital stay; all-cause in-hospital mortality; and the incidence of other complications during hospitalization.
resultsThere was no significant difference in cumulative opioid consumption between the control group (3020.0 [2163.0, 3569.5] µg of remifentanil equivalents) and the PSNB group (2856.0 [2204.0, 3771.0] µg; p = 0.863). The incidence of moderate to severe pain at the donor site within 48 h after surgery was significantly lower in the PSNB group (3 [8.1%] of 37 patients) than in the control group (18 [48.6%] of 37 patients; p < 0.001). The consumption of rescue opioids was significantly reduced in the PSNB group (0 [0, 50]) compared with that in the control group (50 [0, 100]; p = 0.007). The subjective sleep quality numeric rating scale score was significantly lower in the PSNB group than in the control group (day of surgery: 6.0 [5.0, 8.0] vs. 8.0 [6.0, 9.0], p = 0.029; postoperative day 1: 5.0 [4.0, 5.0] vs. 7.0 [5.5, 7.5], p < 0.001; postoperative day 2: 5.0 [4.0, 5.5] vs. 6.0 [5.0, 7.5], p = 0.001). The incidence of postoperative nausea and vomiting was significantly lower in the PSNB group (0 [0.0%]) compared with that in the control group (5 [13.5%]; p = 0.021). There was no significant difference in the incidence of adverse events between the two groups.
conclusionPreoperative administration of PSNB by LB did not spare opioids during the intraoperative period, but significantly relieved postoperative pain at the donor site, reduced rescue opioid consumption, and improved postoperative sleep quality, without additional adverse events.
trial registrationClinicaltrials.gov. Identifier ChiCTR2400080944, 19 February 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.